Enhancer of zeste homolog 2 (EZH2), which is a major contributor to androgen-independent signaling in prostate cancer [17], represses RUNX1 transcription, and the expression of RUNX1 is negatively associated with EZH2 in clinical samples. Here, EZH2 is linked to prostate carcinoma.